immunogenicity highly attenuated mva smallpox vaccine protection monkeypox 
potential use smallpox biological weapon led production stockpiling smallpox vaccine immunization healthcare workers another public health goal licensing safer vaccine benefit millions people advised take current one contacts increased susceptibility severe vaccine side effects1 vaccines can longer tested ability prevent smallpox licensing will necessarily include comparative immunogenicity protection studies non-human primates compare highly attenuated modified vaccinia virus ankara mva2 licensed dryvax vaccine monkey model two doses mva one dose mva followed dryvax antibody binding neutralizing titres t-cell responses equivalent higher induced dryvax alone challenge monkeypox virus unimmunized animals developed pustular skin lesions became gravely ill died whereas vaccinated animals healthy asymptomatic except small number transient skin lesions animals immunized mva 
